Effectiveness of pelvic floor muscle training alone or combined with either a novel biofeedback device or conventional biofeedback for improving stress urinary incontinence: A randomized controlled pilot trial.

PURPOSE: To (i) compare the acceptance of a newly developed, novel biofeedback device (PelviSense) with that of conventional biofeedback (CB) using an intravaginal probe for the treatment of stress urinary incontinence (SUI) in women, (ii) examine the feasibility and safety of using the PelviSense device as a pelvic floor muscle (PFM) training (PFMT) adjunct, and (iii) compare the PFMT adherence and effectiveness of CB, the PelviSense device, with PFMT alone for women with SUI. METHODS: An assessor-blinded, three-arm, randomized controlled pilot trial was conducted among 51 women with SUI. Women were randomly allocated to one of three study groups (PelviSense-assisted PFMT, CB-assisted PFMT, or PFMT alone [control]). Outcome measures included the International Consultation on Incontinence Questionnaire-Short Form, the 1-h pad test, and the Modified Oxford Scale. RESULTS: Participants in the PelviSense-assisted PFMT group expressed good device acceptance. PFMT adherence was greater in the PelviSense-assisted PFMT group than in the unassisted or CB-assisted PFMT groups. Between-groups analysis revealed significant effects on improved SUI symptoms, urine loss severity, and PFM strength for the PelviSense-assisted PFMT group compared with the CB-assisted and PFMT alone groups. CONCLUSIONS: The pilot trial results demonstrated moderate to high PFMT adherence in the PelviSense-assisted PFMT group and supported the safety of using the PelviSense device. The preliminary results of the pilot trial showed that PelviSense-assisted PFMT was more effective for reducing SUI symptoms among women than unassisted or CB-assisted PFMT. TRIAL REGISTRATION: This trial was registered in http://ClinicalTrials.gov (reference number: NCT04638348) before the recruitment of the first participant.

Association between body mass index and risk of formation of breast cancer in Chinese women.

OBJECTIVE: To analyse the association between body mass index (BMI) and breast cancer risk among Chinese women in Hong Kong. METHODS: We conducted a population-based case control study of breast cancer in June 2002. Standardized questionnaires concerning BMI and other anthropometric data were completed by patients at the Queen Mary Hospital (QMH). The cases were 198 women aged 24-85 years who had documented breast cancer in 1995-2000 by triple assessment criteria, and the controls were 353 women who were followed up at QMH for benign breast disease after breast cancer had been excluded by triple assessment. The controls were frequency-matched to the cases by age. RESULTS: BMI at diagnosis was positively correlated with the risk of breast cancer among postmenopausal women (p < 0.001 for trend). Also, when compared with women with a low BMI (< 19), women with a BMI of 23-27 and 27-31 had a 1.73-fold (95% confidence interval, CI, 1.04-2.86) and 2.06-fold (95% CI, 1.08-3.93) increased risk of breast cancer, respectively, after adjustment for non-anthropometric risk factors. BMI at diagnosis, however, was not related to the risk of breast cancer among premenopausal women. The odds ratios for premenopausal women with a BMI of 23-27 and 27-31 were 1.5 (95% CI, 0.82-2.71) and 1.32 (95% CI, 0.39-4.43), respectively. Furthermore, present BMI and BMI 5 years before diagnosis were poorly associated with breast cancer risk among both pre- and postmenopausal women. CONCLUSION: Weight control in obese women may be an effective measure for breast cancer prevention in postmenopausal women.